SCHEMBL16201431

SCHEMBL16201431

CCCN(C)Cc1c[nH]nc1-c1ccc(OCCCN2CCOCC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 9/20 0.55
ALDH1A1 P00352 5/20 0.55
MAPK1 P28482 3/20 0.55
CYP1A2 P05177 1/20 0.55
CHRM2 P08172 1/20 0.55
CHRM1 P11229 1/20 0.55
HTR2A P28223 1/20 0.55
SCN1A P35498 1/20 0.55
HTR2B P41595 1/20 0.55
KCNH2 Q12809 1/20 0.55
SCN2A Q99250 1/20 0.55
SIGMAR1 Q99720 1/20 0.55
SCN3A Q9NY46 1/20 0.55
USP2 O75604 2/20 0.54
LMNA P02545 2/20 0.54
HRH2 P25021 1/20 0.47
HRH1 P35367 1/20 0.47
BCHE P06276 1/20 0.45
ACHE P22303 1/20 0.45
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201426 0.95 NPC1 (0.47) HRH3ALDH1A1MAPK1CYP1A2CHRM2
SCHEMBL16201272 0.91 HRH3 (0.48) HRH3ALDH1A1MAPK1CYP1A2CHRM2
SCHEMBL16201262 0.86 NPC1 (0.47) HRH3ALDH1A1MAPK1CYP1A2CHRM2
SCHEMBL19431991 0.84 PRMT1 (0.45) HRH3ACHETSHRSMN1; SMN2
SCHEMBL16201430 0.80 CYP19A1 (0.40) CYP1A2
SCHEMBL16201438 0.80 NR1I2 (0.38) CYP1A2SMN1; SMN2
SCHEMBL19432034 0.80 NPC1 (0.42) HRH3ALDH1A1ACHETSHRSMN1; SMN2
SCHEMBL20802318 0.80 BCHE (0.43) ALDH1A1BCHEACHETSHRSMN1; SMN2
SCHEMBL16201419 0.79 MEN1 (0.41) ALDH1A1LMNASMN1; SMN2
SCHEMBL19432314 0.77 PRMT1 (0.56) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776972-B2 Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof EPIZYME INC. (US) 2017-10-03 US disclosed
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-05-19 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 HRH3 1068/4885ALDH1A1 686/4885MAPK1 2329/4885
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 HRH3 928/4885ALDH1A1 895/4885MAPK1 1952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.